• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

供体编码的着丝粒KIR B含量的存在增加了接受清髓性、T细胞去除、HLA匹配的造血干细胞移植治疗急性髓细胞白血病患者的感染性死亡风险。

Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML.

作者信息

Bultitude Will P, Schellekens Jennifer, Szydlo Richard M, Anthias Chloe, Cooley Sarah A, Miller Jeffrey S, Weisdorf Daniel J, Shaw Bronwen E, Roberts Chrissy H, Garcia-Sepulveda Christian A, Lee Julia, Pearce Rachel M, Wilson Marie C, Potter Michael N, Byrne Jenny L, Russell Nigel H, MacKinnon Stephen, Bloor Adrian J, Patel Amit, McQuaker I Grant, Malladi Ram, Tholouli Eleni, Orchard Kim, Potter Victoria T, Madrigal J Alejandro, Mayor Neema P, Marsh Steven G E

机构信息

Anthony Nolan Research Institute, Royal Free Hospital, London, UK.

Cancer Institute, University College London, Royal Free Campus, London, UK.

出版信息

Bone Marrow Transplant. 2020 Oct;55(10):1975-1984. doi: 10.1038/s41409-020-0858-9. Epub 2020 Mar 13.

DOI:10.1038/s41409-020-0858-9
PMID:32203258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8852820/
Abstract

The reported influence of donor Killer-cell Immunoglobulin-like Receptor (KIR) genes on the outcomes of haematopoietic cell transplantation (HCT) are contradictory, in part due to diversity of disease, donor sources, era and conditioning regimens within and between different studies. Here, we describe the results of a retrospective clinical analysis establishing the effect of donor KIR motifs on the outcomes of 119 HLA-matched, unrelated donor HCT for adult acute myeloid leukaemia (AML) using myeloablative conditioning (MAC) in a predominantly T-cell deplete (TCD) cohort. We observed that HCT involving donors with at least one KIR B haplotype were more likely to result in non-relapse mortality (NRM) than HCT involving donors with two KIR A haplotypes (p = 0.019). Upon separation of KIR haplotypes into their centromeric (Cen) and telomeric (Tel) motif structures, we demonstrated that the Cen-B motif was largely responsible for this effect (p = 0.001). When the cause of NRM was investigated further, infection was the dominant cause of death (p = 0.006). No evidence correlating donor KIR B haplotype with relapse risk was observed. The results from this analysis confirm previous findings in the unrelated, TCD, MAC transplant setting and imply a protective role for donor-encoded Cen-A motifs against infection in allogeneic HCT recipients.

摘要

供体杀伤细胞免疫球蛋白样受体(KIR)基因对造血细胞移植(HCT)结果的影响报道相互矛盾,部分原因是不同研究内部和之间疾病、供体来源、时代和预处理方案的多样性。在此,我们描述了一项回顾性临床分析的结果,该分析确定了供体KIR基序对119例接受清髓性预处理(MAC)的成人急性髓系白血病(AML)患者进行HLA匹配的无关供体HCT结果的影响,该队列主要为T细胞去除(TCD)。我们观察到,与具有两个KIR A单倍型的供体进行的HCT相比,涉及至少具有一个KIR B单倍型供体的HCT更有可能导致非复发死亡率(NRM)(p = 0.019)。将KIR单倍型分离为其着丝粒(Cen)和端粒(Tel)基序结构后,我们证明Cen - B基序在很大程度上导致了这种影响(p = 0.001)。当进一步调查NRM的原因时,感染是主要的死亡原因(p = 0.006)。未观察到供体KIR B单倍型与复发风险相关的证据。该分析结果证实了在无关、TCD、MAC移植环境中的先前发现,并暗示供体编码的Cen - A基序对异基因HCT受者的感染具有保护作用。

相似文献

1
Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML.供体编码的着丝粒KIR B含量的存在增加了接受清髓性、T细胞去除、HLA匹配的造血干细胞移植治疗急性髓细胞白血病患者的感染性死亡风险。
Bone Marrow Transplant. 2020 Oct;55(10):1975-1984. doi: 10.1038/s41409-020-0858-9. Epub 2020 Mar 13.
2
Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.供者选择具有中央元件的杀伤细胞免疫球蛋白样受体 B 单倍型可改善 HLA 相合同胞造血干细胞移植后的结局。
Biol Blood Marrow Transplant. 2014 Jan;20(1):98-105.
3
Donor genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.供者基因型异基因造血干细胞移植后结局预测:前路漫漫。
Front Immunol. 2024 Apr 2;15:1350470. doi: 10.3389/fimmu.2024.1350470. eCollection 2024.
4
Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.KIR基因型的供受者匹配可减少慢性移植物抗宿主病,且缺乏抑制性KIR配体可预防清髓性、HLA匹配的造血细胞移植后的复发。
PLoS One. 2016 Jun 24;11(6):e0158242. doi: 10.1371/journal.pone.0158242. eCollection 2016.
5
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.具有B组KIR单倍型的供者可改善急性髓性白血病无关造血细胞移植后的无复发生存率。
Blood. 2009 Jan 15;113(3):726-32. doi: 10.1182/blood-2008-07-171926. Epub 2008 Oct 22.
6
Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.供者杀伤细胞免疫球蛋白样受体 B 单倍型、受者 HLA-C1 和 HLA-C 错配增强了无关造血干细胞移植治疗急性髓系白血病的临床获益。
J Immunol. 2014 May 15;192(10):4592-600. doi: 10.4049/jimmunol.1302517. Epub 2014 Apr 18.
7
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.自然杀伤细胞受体基因供者选择可提高急性髓细胞白血病非亲缘移植后的生存。
Blood. 2010 Oct 7;116(14):2411-9. doi: 10.1182/blood-2010-05-283051. Epub 2010 Jun 25.
8
Donor Killer Immunoglobulin-Like Receptor Profile Bx1 Imparts a Negative Effect and Centromeric B-Specific Gene Motifs Render a Positive Effect on Standard-Risk Acute Myeloid Leukemia/Myelodysplastic Syndrome Patient Survival after Unrelated Donor Hematopoietic Stem Cell Transplantation.供体杀伤细胞免疫球蛋白样受体谱Bx1产生负面影响,而着丝粒B特异性基因基序对无关供体造血干细胞移植后标准风险急性髓系白血病/骨髓增生异常综合征患者的生存产生积极影响。
Biol Blood Marrow Transplant. 2016 Feb;22(2):232-239. doi: 10.1016/j.bbmt.2015.09.007. Epub 2015 Sep 11.
9
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.KIR B 供者可改善接受低强度预处理和无关供者移植的 AML 患者的结局。
Blood Adv. 2020 Feb 25;4(4):740-754. doi: 10.1182/bloodadvances.2019001053.
10
Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.基于单倍型基序的模型用于基于 KIR 基因型的造血细胞供者选择,无法预测骨髓增生异常综合征或继发性急性髓系白血病患者的结局。
Front Immunol. 2021 Jan 19;11:584520. doi: 10.3389/fimmu.2020.584520. eCollection 2020.

引用本文的文献

1
Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin.基于KIR-HLA相互作用的自然杀伤细胞同种异体反应性对接受抗胸腺细胞球蛋白的儿童单倍体相合移植复发的预测及影响
Front Immunol. 2025 Aug 26;16:1643244. doi: 10.3389/fimmu.2025.1643244. eCollection 2025.
2
An In-Depth Review of the Genetics of the Non-Classical HLA Class I Gene HLA-E and Its Effects on Haematopoietic Cell Transplant Outcomes.非经典 HLA I 类基因 HLA-E 的遗传学及其对造血细胞移植结果影响的深入综述
HLA. 2025 Aug;106(2):e70344. doi: 10.1111/tan.70344.
3
Role of Centromeric and Telomeric Haplotypes of Killer-Cell Immunoglobulin-Like Receptors (KIRs) in Disease Susceptibility: A Research Review.杀伤细胞免疫球蛋白样受体(KIRs)着丝粒和端粒单倍型在疾病易感性中的作用:一项研究综述。
Cureus. 2025 May 8;17(5):e83728. doi: 10.7759/cureus.83728. eCollection 2025 May.
4
NK cell defects: implication in acute myeloid leukemia.自然杀伤细胞缺陷:在急性髓系白血病中的意义。
Front Immunol. 2023 May 9;14:1112059. doi: 10.3389/fimmu.2023.1112059. eCollection 2023.
5
Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.供者杀伤细胞免疫球蛋白受体基因含量及配体匹配与儿童幼年型粒单核细胞白血病患者无关供者移植后结局的关系。
Transplant Cell Ther. 2021 Nov;27(11):926.e1-926.e10. doi: 10.1016/j.jtct.2021.08.009. Epub 2021 Aug 15.
6
Following Transplantation for Acute Myelogenous Leukemia, Donor Better Protects against Relapse than .异基因造血干细胞移植后,供者比受者更能预防疾病复发。
J Immunol. 2021 Jun 15;206(12):3064-3072. doi: 10.4049/jimmunol.2100119. Epub 2021 Jun 11.
7
Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.KIR 和 NK 细胞重建对造血干细胞移植结局的影响。
Front Immunol. 2020 Sep 2;11:2022. doi: 10.3389/fimmu.2020.02022. eCollection 2020.

本文引用的文献

1
Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study.供体激活型KIR基因对接受无关供体移植的C1配体阴性髓系疾病患者造血干细胞移植结局的影响——一项回顾性研究
PLoS One. 2017 Jan 20;12(1):e0169512. doi: 10.1371/journal.pone.0169512. eCollection 2017.
2
Estimating KIR Haplotype Frequencies on a Cohort of 10,000 Individuals: A Comprehensive Study on Population Variations, Typing Resolutions, and Reference Haplotypes.估计一万名个体队列中的杀伤细胞免疫球蛋白样受体单倍型频率:关于群体变异、分型分辨率和参考单倍型的综合研究
PLoS One. 2016 Oct 10;11(10):e0163973. doi: 10.1371/journal.pone.0163973. eCollection 2016.
3
Sensitivity of dendritic cells to NK-mediated lysis depends on the inflammatory environment and is modulated by CD54/CD226-driven interactions.树突状细胞对 NK 介导的裂解的敏感性取决于炎症环境,并受 CD54/CD226 驱动的相互作用调节。
J Leukoc Biol. 2016 Oct;100(4):781-789. doi: 10.1189/jlb.3A0615-271RR. Epub 2016 Mar 31.
4
KIR2DL2/2DL3-E(35) alleles are functionally stronger than -Q(35) alleles.KIR2DL2/2DL3-E(35)等位基因在功能上比-Q(35)等位基因更强。
Sci Rep. 2016 Mar 31;6:23689. doi: 10.1038/srep23689.
5
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.供者特征对血液系统恶性肿瘤异基因供者移植后生存的影响。
Blood. 2016 Jan 14;127(2):260-7. doi: 10.1182/blood-2015-08-663823. Epub 2015 Nov 2.
6
KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study.基于受体-配体模型的杀伤细胞免疫球蛋白样受体同种异体反应性与异基因造血干细胞移植的临床疗效改善相关:单中心前瞻性研究结果
Hum Immunol. 2015 Sep;76(9):636-43. doi: 10.1016/j.humimm.2015.09.009. Epub 2015 Sep 25.
7
Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.KIR 配体错配供者的单倍体造血移植伴有激活型 KIR 可降低非复发死亡率。
Blood. 2015 May 14;125(20):3173-82. doi: 10.1182/blood-2014-09-599993. Epub 2015 Mar 13.
8
Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.供者杀伤细胞免疫球蛋白样受体 B 单倍型、受者 HLA-C1 和 HLA-C 错配增强了无关造血干细胞移植治疗急性髓系白血病的临床获益。
J Immunol. 2014 May 15;192(10):4592-600. doi: 10.4049/jimmunol.1302517. Epub 2014 Apr 18.
9
Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.KIR2DL3 等位基因变异产生一种与 KIR2DL2 相似的受体,其与 HLA-C 配体的结合能力增强。
J Immunol. 2013 Jun 15;190(12):6198-208. doi: 10.4049/jimmunol.1300464. Epub 2013 May 17.
10
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.HLA-C 依赖性供体激活 KIR2DS1 预防白血病复发。
N Engl J Med. 2012 Aug 30;367(9):805-16. doi: 10.1056/NEJMoa1200503.